Adaptive Biotechnologies Corp
Company Profile
Business description
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Contact
1165 Eastlake Avenue East
SeattleWA98109
USAT: +1 206 659-0067
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
624
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
stocks
Investor Playbook: Can your portfolio handle what’s next?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,400.89 | 31.98 | 0.38% |
| DAX 40 | 26,753.05 | 3.10 | 0.01% |
| Dow JONES (US) | 52,182.65 | 164.90 | -0.32% |
| FTSE 100 | 10,950.05 | 47.49 | 0.44% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,787.57 | 348.70 | -1.39% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,493.86 | 67.81 | -0.90% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |